Kakuhiro Yamaguchi 研究室

主宰者：Kakuhiro Yamaguchi

広島大学・Hiroshima University Hospital

AI 要約（直近 5 年の研究成果）

本研究室は、肺がんの免疫治療に対する耐性機構の解明と克服を主な研究テーマとしています。特に、免疫チェックポイント阻害薬（抗PD-1抗体など）の治療中に、一部のがん細胞が生き残る現象に着目し、その分子基盤を調べています。マウスの腫瘍モデルを用いた実験系と患者サンプルの分析を組み合わせ、治療後に生き残るがん細胞がどのような遺伝子発現パターンを示すかを検討しています。これまでの研究で、プラスミノーゲン活性化因子インヒビター1（PAI-1）というタンパク質が、免疫治療の効果を低下させる重要な役割を果たすことを報告しています。PAI-1の発現制御や、それに関連する細胞間のシグナル伝達経路（TGF-βシグナルなど）が耐性獲得に関わっていることを見出しており、この経路を標的とした治療戦略の開発を進めています。さらに、肺線維症や薬剤性肺障害といった、がん治療に伴う肺の有害事象についても研究を展開しています。腫瘍の存在が治療薬の肺への影響を増幅させるメカニズムや、血清マーカーを用いた重症化予測の可能性についても検討しており、患者の安全性向上に貢献することを目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（100 件）

[2026] Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study
DOI: https://doi.org/10.21037/tlcr-2025-aw-1281
[2026] Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan
DOI: https://doi.org/10.1016/j.ejca.2026.116232
[2026] OA03.02: A Nationwide Study on Driver Mutation Testing and Targeted Therapies in NSCLC patients with comorbid Interstitial Pneumonia
DOI: https://doi.org/10.1016/j.jtho.2025.12.018
[2026] Supplementary References from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443150
[2026] Supplementary Figure S3 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443180
[2026] Supplementary Figure S4 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443177
[2026] Supplementary Figure S11 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443186
[2026] Supplementary Figure S10 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443189
[2026] Supplementary Figure S5 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443174
[2026] Supplementary Figure S6 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443171

続きを表示（残り 90 件）

[2026] Supplementary Figure S7 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443168
[2026] Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs
DOI: https://doi.org/10.1007/s10147-026-03083-2
[2026] Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation
DOI: https://doi.org/10.1002/resp.70267
[2026] A multi-institutional, single-arm, phase 2 study of durvalumab plus amrubicin in patients with relapsed extensive-stage small cell lung cancer (Aphrodite trial).
DOI: https://doi.org/10.1200/jco.2026.44.16_suppl.8105
[2026] Clinical utility of the bronchial washing-to-serum galactomannan antigen ratio for the diagnosis of pulmonary aspergillosis
DOI: https://doi.org/10.1016/j.mimet.2026.107556
[2026] Incidence of leptomeningeal metastasis and prognosis after its development in patients with advanced non-small cell lung cancer: a prospective real-world observational study (CS-Lung-003-linked study 37)
DOI: https://doi.org/10.1016/j.ijlcan.2026.100031
[2026] Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation
DOI: https://doi.org/10.1111/1759-7714.70272
[2026] Supplementary Figure S2 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443183
[2026] Supplementary Figure S9 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443159
[2026] Supplementary Figure S8 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443165
[2026] Supplementary Figure S1 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443192
[2026] Supplementary Methods from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443153
[2026] Data from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.c.8332089
[2026] Supplementary Table S1 from Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.31443147
[2025] Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer
DOI: https://doi.org/10.3390/cancers17040572
[2025] Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
DOI: https://doi.org/10.1177/17588359251318850
[2025] Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study
DOI: https://doi.org/10.1177/17588359241312503
[2025] Two Cases of Epidermal Growth Factor Receptor <scp>L861R</scp> Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib
DOI: https://doi.org/10.1002/cnr2.70420
[2025] Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.mct-24-0890
[2025] Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppression
DOI: https://doi.org/10.1016/j.omtn.2025.102765
[2025] Diffuse Pulmonary Meningotheliomatosis Presenting with the Cheerios Sign Diagnosed by a Transbronchial Lung Cryobiopsy
DOI: https://doi.org/10.2169/internalmedicine.6181-25
[2025] The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)
DOI: https://doi.org/10.1016/j.ejca.2025.115606
[2025] Exogenous Lipoid Pneumonia Induced by the Excessive Use of Menthol-containing Nasal Inhalers and Subsequent Acute Hypersensitivity Pneumonia Triggered by Domestic Environmental Antigens
DOI: https://doi.org/10.2169/internalmedicine.5358-25
[2025] Cisplatin-induced Severe Renal Salt-wasting Syndrome Complicated with Hypovolemic Shock and Various Electrolyte Abnormalities in a Patient with Thymoma
DOI: https://doi.org/10.2169/internalmedicine.5218-24
[2025] Serum Soluble Toll-Like Receptor 4 is a Predictive Biomarker for Acute Exacerbation and Prognosis of Idiopathic Pulmonary Fibrosis: A Retrospective Study
DOI: https://doi.org/10.1007/s00408-025-00800-y
[2025] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
DOI: https://doi.org/10.1007/s00280-025-04751-2
[2024] Primary pulmonary extranodal NK/T-cell lymphoma diagnosed by thoracoscopic lung biopsy: A case report
DOI: https://doi.org/10.1016/j.rmcr.2024.102127
[2024] Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort study
DOI: https://doi.org/10.1186/s12931-024-03014-7
[2024] Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study
DOI: https://doi.org/10.1111/1759-7714.15469
[2024] A Case of Granulocyte-Colony-Stimulating Factor-Producing Non-Small Cell Lung Cancer under Steroid Treatment and with Poor Performance Status That Responded to Pembrolizumab
DOI: https://doi.org/10.1159/000540935
[2024] P4.11E.15 Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab
DOI: https://doi.org/10.1016/j.jtho.2024.09.728
[2024] Sex-related differences in efficacy of bone marrow-derived high aldehyde dehydrogenase activity cells against pulmonary fibrosis
DOI: https://doi.org/10.1186/s13287-024-03933-8
[2024] Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis
DOI: https://doi.org/10.1186/s12931-024-02825-y
[2024] A Case of Miliary Pulmonary Cryptococcosis Showing Different Changes in Computed Tomography Images of the Left and Right Lungs
DOI: https://doi.org/10.58585/respend.2023-0045
[2024] High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis
DOI: https://doi.org/10.1136/bmjresp-2023-001803
[2024] Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
DOI: https://doi.org/10.1007/s00408-023-00669-9
[2024] Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia
DOI: https://doi.org/10.1183/23120541.00981-2023
[2023] Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition
DOI: https://doi.org/10.3390/cancers15041092
[2023] Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases
DOI: https://doi.org/10.2169/internalmedicine.2387-23
[2023] A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
DOI: https://doi.org/10.1016/j.lungcan.2023.01.011
[2023] Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis
DOI: https://doi.org/10.3390/medicina59101776
[2023] Hypoxia-inducible factor 1α modulates interstitial pneumonia-mediated lung cancer progression
DOI: https://doi.org/10.1186/s12967-023-04756-6
[2023] O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
DOI: https://doi.org/10.1016/j.annonc.2023.09.128
[2023] P29-8 A study of lung cancer cases who participated in cancer genome medicine at our hospital
DOI: https://doi.org/10.1016/j.annonc.2023.09.367
[2023] MA05.10 Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
DOI: https://doi.org/10.1016/j.jtho.2023.09.149
[2023] Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
DOI: https://doi.org/10.1016/j.jtocrr.2023.100593
[2023] A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps8612
[2023] Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan
DOI: https://doi.org/10.1016/j.jiac.2023.05.013
[2023] Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases
DOI: https://doi.org/10.1016/j.rmed.2023.107224
[2023] Preserved ratio impaired spirometry with or without restrictive spirometric abnormality
DOI: https://doi.org/10.1038/s41598-023-29922-0
[2023] Rehabilitation Medicine for Lung Cancer in the Era of Molecularly Targeted Therapy
DOI: https://doi.org/10.2490/jjrmc.60.129
[2023] Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial–mesenchymal transition in lung endothelial cells
DOI: https://doi.org/10.1186/s12964-023-01099-z
[2023] Intestinal overgrowth of <scp>Candida albicans</scp> exacerbates bleomycin‐induced pulmonary fibrosis in mice with dysbiosis
DOI: https://doi.org/10.1002/path.6169
[2022] Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
DOI: https://doi.org/10.1186/s12890-022-02037-4
[2022] Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis
DOI: https://doi.org/10.1111/resp.14425
[2022] Prediction model for patient prognosis in idiopathic pulmonary fibrosis using hybrid radiomics analysis
DOI: https://doi.org/10.1016/j.redii.2022.100017
[2022] Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e21156
[2022] Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high <scp>PD‐L1</scp>
DOI: https://doi.org/10.1111/1759-7714.14428
[2022] Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer
DOI: https://doi.org/10.1016/j.jpainsymman.2022.04.171
[2022] Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis
DOI: https://doi.org/10.2169/internalmedicine.8413-21
[2022] First‐line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor<scp>G719S</scp> and de novo <scp>T790M</scp> mutations
DOI: https://doi.org/10.1111/1759-7714.14288
[2022] A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy
DOI: https://doi.org/10.2139/ssrn.4309667
[2022] Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy
DOI: https://doi.org/10.1007/s10147-022-02239-0
[2022] Association Between Patient Preference for Inhaler Medications and Asthma Outcomes
DOI: https://doi.org/10.2147/jaa.s381509
[2021] Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report
DOI: https://doi.org/10.1080/02770903.2021.2022158
[2021] P1‐55: Pulmonary function after nintedanib treatment in post‐COVID‐19 pulmonary fibrosis
DOI: https://doi.org/10.1111/resp.14150_55
[2021] O24‐1: Regulation of SMAD7 and SOCS1 through metabolic and epigenetics coordination by mesenchymal stem cell‐derived humoral factor STC1 induces anti‐fibrotic and anti‐inflammatory effects in lung injuries
DOI: https://doi.org/10.1111/resp.14149_140
[2021] O24‐2: The role of circulatory high‐mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti‐PD‐1/PD‐L1 antibody monotherapy
DOI: https://doi.org/10.1111/resp.14149_141
[2021] Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report
DOI: https://doi.org/10.1159/000518315
[2021] Accelerated decline in lung function in adults with a history of remitted childhood asthma
DOI: https://doi.org/10.1183/13993003.00305-2021
[2021] Tolerability and efficacy of <scp>IMpower133</scp> regimen modified for dialysis patients with extensive‐stage small cell lung cancer: Two case reports
DOI: https://doi.org/10.1111/1759-7714.14166
[2021] Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4
DOI: https://doi.org/10.2169/internalmedicine.7436-21
[2021] Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis
DOI: https://doi.org/10.1186/s13287-021-02574-5
[2021] IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis
DOI: https://doi.org/10.1371/journal.pone.0252594
[2021] Elevated leukocyte count predicts survival in patients with idiopathic pulmonary fibrosis: analysis from the Swedish and Japanese cohorts
DOI: https://doi.org/10.1183/13993003.congress-2021.pa393
[2021] Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity
DOI: https://doi.org/10.1186/s13287-021-02549-6
[2021] Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia
DOI: https://doi.org/10.2169/internalmedicine.7432-21
[2021] Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
DOI: https://doi.org/10.1007/s00280-021-04341-y
[2021] Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis
DOI: https://doi.org/10.1186/s13023-021-01926-x
[2021] MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers
DOI: https://doi.org/10.1016/j.annonc.2021.05.585
[2021] Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report
DOI: https://doi.org/10.1007/s12328-020-01315-0
[2021] D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis
DOI: https://doi.org/10.1097/md.0000000000024695
[2021] Risk factors associated with increased discontinuation rate of trimethoprim–sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study
DOI: https://doi.org/10.1016/j.pupt.2021.101999
[2021] A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
DOI: https://doi.org/10.1016/j.cllc.2020.12.009
[2021] Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury
DOI: https://doi.org/10.1016/j.athoracsur.2021.05.059
[2021] Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients
DOI: https://doi.org/10.1038/s41598-021-89663-w
[2021] Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone
DOI: https://doi.org/10.21873/anticanres.15047
[2021] Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report
DOI: https://doi.org/10.1080/02770903.2021.1910294
[2021] Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer
DOI: https://doi.org/10.21873/anticanres.14908
[2021] A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia
DOI: https://doi.org/10.1097/md.0000000000024738

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（100 件）

科研費（0 件）

所属学会・役職（0 件）